Natera, Inc. (NASDAQ:NTRA) Receives $260.33 Consensus Price Target from Analysts

Natera, Inc. (NASDAQ:NTRA) has been assigned an average rating of “Moderate Buy” from the twenty-two research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $262.00.

NTRA has been the subject of several research analyst reports. Sanford C. Bernstein started coverage on shares of Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price objective for the company. Barclays decreased their price target on shares of Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, June 24th. Piper Sandler reiterated an “overweight” rating and set a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. Wells Fargo & Company increased their price objective on shares of Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Finally, Guggenheim raised their target price on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, June 29th.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rowan E. Chapman sold 2,964 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the sale, the director directly owned 3,124 shares of the company’s stock, valued at approximately $677,220.72. This represents a 48.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,872 shares of company stock worth $39,627,696 in the last three months. 5.05% of the stock is owned by corporate insiders.

Institutional Trading of Natera

Hedge funds and other institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc lifted its stake in Natera by 38.1% in the 2nd quarter. Versant Capital Management Inc now owns 779 shares of the medical research company’s stock worth $211,000 after purchasing an additional 215 shares in the last quarter. Roxbury Financial LLC raised its position in shares of Natera by 458.2% in the second quarter. Roxbury Financial LLC now owns 5,024 shares of the medical research company’s stock worth $1,364,000 after buying an additional 4,124 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of Natera by 3.4% in the first quarter. NewEdge Advisors LLC now owns 5,452 shares of the medical research company’s stock worth $1,090,000 after buying an additional 179 shares in the last quarter. Groupama Asset Managment boosted its stake in Natera by 3.0% during the first quarter. Groupama Asset Managment now owns 95,061 shares of the medical research company’s stock valued at $19,011,000 after buying an additional 2,805 shares during the period. Finally, Oddo BHF Asset Management Sas purchased a new position in Natera during the first quarter worth about $6,410,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Down 0.6%

NTRA traded down $1.62 during trading on Thursday, hitting $282.18. The company’s stock had a trading volume of 433,004 shares, compared to its average volume of 1,374,239. Natera has a twelve month low of $131.81 and a twelve month high of $288.04. The stock’s fifty day moving average price is $221.45 and its 200-day moving average price is $217.64. The firm has a market capitalization of $40.41 billion, a P/E ratio of -174.06 and a beta of 1.51.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.